Efficacy of abiraterone acetate in post-docetaxel castration-resistant prostate cancer

Targeted therapy for advanced prostate cancer: Looking through new lenses

(2010) P. Vogiatzi et al.   DRUG NEWS & PERSPECTIVES

Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

(2010) Charles J. Ryan et al.   JOURNAL OF CLINICAL ONCOLOGY

Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate

(2010) Alison H.M. Reid et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

(2010) Howard I Scher et al.   LANCET

Update: Immunological Strategies for Prostate Cancer

(2010) Charles G. Drake et al.   Current Urology Reports

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

(2009) J E Ang et al.   BRITISH JOURNAL OF CANCER

Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?

(2009) Gerhardt Attard et al.   CANCER CELL

Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven

(2009) G. Attard et al.   CANCER RESEARCH

Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial

(2009) Jacques Irani et al.   LANCET ONCOLOGY

Eradication of Therapy-resistant Human Prostate Tumors Using an Ultrasound-guided Site-specific Cancer Terminator Virus Delivery Approach

(2009) Adelaide Greco et al.   MOLECULAR THERAPY

Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience

(2008) D. Olmos et al.   ANNALS OF ONCOLOGY

Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17)—Part II: Core rigidification and influence of substituents at the methylene bridge

(2008) Qingzhong Hu et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven

(2008) Gerhardt Attard et al.   JOURNAL OF CLINICAL ONCOLOGY

Synthesis, Biological Evaluation, and Molecular Modeling of Abiraterone Analogues: Novel CYP17 Inhibitors for the Treatment of Prostate Cancer

(2008) Mariano A. E. Pinto-Bazurco Mendieta et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Coffey Lecture: Steroidogenic enzyme inhibitors and hormone dependent cancer

(2008) Angela Brodie et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS